drugset / Trial / NCT00102115
Study of Talaporfin Sodium Photodynamic Therapy to Treat Advanced Age Related Macular Disease
Non-randomizedCrossoverOpen-labelTreatment
Summary
The purpose of this study is to determine the safety and tolerability of Talaporfin Sodium (LS11) Photodynamic Therapy in patients with late stage Age-Related Macular Disease (AMD).
Timeline
- Start
- 2004-12
- Primary completion
- —
- Completion
- 2006-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Talaporfin | Other / unclassified | 0.2 mg/kg | — |
| Subject | Talaporfin | Other / unclassified | 0.5 mg/kg | — |